Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.16
NYSE:ZTS's Cash to Debt is ranked lower than
87% of the 790 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.44 vs. NYSE:ZTS: 0.16 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:ZTS' s Cash to Debt Range Over the Past 10 Years
Min: 0.14  Med: 0.24 Max: N/A
Current: 0.16
Equity to Asset 0.19
NYSE:ZTS's Equity to Asset is ranked lower than
94% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. NYSE:ZTS: 0.19 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:ZTS' s Equity to Asset Range Over the Past 10 Years
Min: 0.14  Med: 0.2 Max: 0.65
Current: 0.19
0.14
0.65
Interest Coverage 8.40
NYSE:ZTS's Interest Coverage is ranked lower than
75% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 94.32 vs. NYSE:ZTS: 8.40 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:ZTS' s Interest Coverage Range Over the Past 10 Years
Min: 2.3  Med: 8.42 Max: 22.42
Current: 8.4
2.3
22.42
F-Score: 7
Z-Score: 4.38
M-Score: -2.39
WACC vs ROIC
10.37%
18.18%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 28.54
NYSE:ZTS's Operating margin (%) is ranked higher than
91% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.64 vs. NYSE:ZTS: 28.54 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:ZTS' s Operating margin (%) Range Over the Past 10 Years
Min: -4.53  Med: 16.72 Max: 28.58
Current: 28.54
-4.53
28.58
Net-margin (%) 16.80
NYSE:ZTS's Net-margin (%) is ranked higher than
81% of the 737 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.21 vs. NYSE:ZTS: 16.80 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:ZTS' s Net-margin (%) Range Over the Past 10 Years
Min: -3.62  Med: 8.59 Max: 16.8
Current: 16.8
-3.62
16.8
ROE (%) 61.62
NYSE:ZTS's ROE (%) is ranked higher than
97% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.92 vs. NYSE:ZTS: 61.62 )
Ranked among companies with meaningful ROE (%) only.
NYSE:ZTS' s ROE (%) Range Over the Past 10 Years
Min: 11.26  Med: 24.4 Max: 64.27
Current: 61.62
11.26
64.27
ROA (%) 10.73
NYSE:ZTS's ROA (%) is ranked higher than
79% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. NYSE:ZTS: 10.73 )
Ranked among companies with meaningful ROA (%) only.
NYSE:ZTS' s ROA (%) Range Over the Past 10 Years
Min: 4.68  Med: 8.22 Max: 10.73
Current: 10.73
4.68
10.73
ROC (Joel Greenblatt) (%) 48.55
NYSE:ZTS's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.01 vs. NYSE:ZTS: 48.55 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:ZTS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 24.65  Med: 32.08 Max: 50.38
Current: 48.55
24.65
50.38
Revenue Growth (3Y)(%) 2.50
NYSE:ZTS's Revenue Growth (3Y)(%) is ranked lower than
61% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. NYSE:ZTS: 2.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:ZTS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 3.1 Max: 8.4
Current: 2.5
0
8.4
EBITDA Growth (3Y)(%) 17.50
NYSE:ZTS's EBITDA Growth (3Y)(%) is ranked higher than
64% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.50 vs. NYSE:ZTS: 17.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:ZTS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 17.5 Max: 36.2
Current: 17.5
0
36.2
EPS Growth (3Y)(%) 17.80
NYSE:ZTS's EPS Growth (3Y)(%) is ranked higher than
65% of the 539 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.30 vs. NYSE:ZTS: 17.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:ZTS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 17.8 Max: 66.2
Current: 17.8
0
66.2
GuruFocus has detected 4 Warning Signs with Zoetis Inc $NYSE:ZTS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:ZTS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ZTS Guru Trades in Q1 2016

Joel Greenblatt 96,665 sh (New)
Stanley Druckenmiller 477,900 sh (New)
Louis Moore Bacon 13,808 sh (New)
First Eagle Investment 2,812,702 sh (New)
Robert Olstein 82,000 sh (New)
Jim Simons 1,413,100 sh (+398.62%)
Keeley Asset Management Corp 78,974 sh (+119.97%)
Bill Ackman 41,823,145 sh (unchged)
Vanguard Health Care Fund Sold Out
Mario Gabelli 579,052 sh (-2.25%)
Pioneer Investments 3,154,039 sh (-8.77%)
Steven Cohen 3,940,500 sh (-10.74%)
Ruane Cunniff 126,783 sh (-16.34%)
George Soros 2,316,921 sh (-31.58%)
Paul Tudor Jones 12,155 sh (-72.63%)
» More
Q2 2016

ZTS Guru Trades in Q2 2016

Paul Tudor Jones 19,300 sh (+58.78%)
Jim Simons 1,877,500 sh (+32.86%)
Steven Cohen 4,400,417 sh (+11.67%)
Stanley Druckenmiller 477,900 sh (unchged)
Robert Olstein 82,000 sh (unchged)
Ruane Cunniff Sold Out
Louis Moore Bacon Sold Out
Pioneer Investments 3,076,037 sh (-2.47%)
Mario Gabelli 553,656 sh (-4.39%)
Keeley Asset Management Corp 75,274 sh (-4.69%)
First Eagle Investment 2,073,478 sh (-26.28%)
George Soros 1,258,919 sh (-45.66%)
Bill Ackman 21,173,188 sh (-49.37%)
Joel Greenblatt 26,521 sh (-72.56%)
» More
Q3 2016

ZTS Guru Trades in Q3 2016

Eaton Vance Worldwide Health Sciences Fund 317,870 sh (New)
First Eagle Investment 3,893,085 sh (+87.76%)
Steven Cohen 4,645,203 sh (+5.56%)
Mario Gabelli 560,731 sh (+1.28%)
Stanley Druckenmiller 477,900 sh (unchged)
Joel Greenblatt Sold Out
Pioneer Investments 2,918,623 sh (-5.12%)
Keeley Asset Management Corp 66,374 sh (-11.82%)
Robert Olstein 66,000 sh (-19.51%)
Paul Tudor Jones 15,000 sh (-22.28%)
George Soros 831,619 sh (-33.94%)
Jim Simons 1,108,100 sh (-40.98%)
Bill Ackman 2,717,719 sh (-87.16%)
» More
Q4 2016

ZTS Guru Trades in Q4 2016

Manning & Napier Advisors, Inc 290,660 sh (New)
First Eagle Investment 4,390,047 sh (+12.77%)
Eaton Vance Worldwide Health Sciences Fund 828,810 sh (+160.74%)
Robert Olstein 66,000 sh (unchged)
Stanley Druckenmiller Sold Out
Bill Ackman Sold Out
George Soros 808,419 sh (-2.79%)
Mario Gabelli 542,583 sh (-3.24%)
Keeley Asset Management Corp 58,525 sh (-11.83%)
Paul Tudor Jones 12,300 sh (-18.00%)
Jim Simons 860,000 sh (-22.39%)
Pioneer Investments 1,583,638 sh (-45.74%)
Steven Cohen 1,026,093 sh (-77.91%)
» More
» Details

Insider Trades

Latest Guru Trades with ZTS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:MYL, NYSE:TEVA, OTCPK:SGIOF, OTCPK:ESALY, OTCPK:TKPYY, OTCPK:MKGAY, NYSE:PRGO, OTCPK:MTZPY, OTCPK:APNHY, OTCPK:SFOSF, OTCPK:HLUYY, NYSE:RDY, OTCPK:IPSEY, OTCPK:HKMPY, NYSE:MNK, NYSE:VRX, OTCPK:HYPMY, NAS:OPK, NYSE:TARO, NYSE:PTHN » details
Traded in other countries:ZOE.Germany,
Zoetis Inc discovers, develops, manufactures & commercializes animal health medicines & vaccines for livestock & companion animals. Its products include anti-infectives, vaccines, parasiticides, medicated feed additives & other pharmaceutical products.

Zoetis Inc was incorporated in Delaware in July 2012. It is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. It has a diversified business, marketing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals); and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company organizes and operates its business in two geographic regions: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio for both livestock and companion animal customers. The Company directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company sells its livestock products directly to a diverse set of livestock producers, including beef and dairy farmers as well as pork, poultry and aquaculture operations, and to veterinarians, third-party veterinary distributors and retail outlets that typically then sell the products to livestock producers. It sells the companion animal products to veterinarians or to third-party veterinary distributors that typically then sell its products to veterinarians, and in each case veterinarians then typically sell its products to pet owners. Its primary competitors include animal health medicines and vaccines companies such as Merck Animal Health, the animal health division of Merck & Co., Inc.; Merial, the animal health division of Sanofi S.A.; Elanco, the animal health division of Eli Lilly and Company; Bayer Animal Health, the animal health division of Bayer AG; and Boehringer Ingelheim Animal Health, the animal health division of Boehringer Ingelheim GmbH. In addition, it competes with hundreds of other animal health product producers throughout the world. It is subject to various federal, state, local and foreign environmental, health and safety laws and regulations.

Guru Investment Theses on Zoetis Inc

Bill Ackman Comments on Zoetis - Dec 09, 2016

On November 9th we sold our last shares of Zoetis (NYSE:ZTS), about two years after we publicly announced an 8.5% ownership stake. Despite the high quality nature of the business and its strong management team, we sold to redeploy the capital in certain new investments.

We purchased our stake in Zoetis at an average cost of approximately $37 per share. Shortly thereafter, we met with the Zoetis management to learn more about the company and to discuss our views on potential initiatives to create shareholder value. On February 4, 2015, Zoetis agreed to add then-Pershing Square investment team member (and healthcare industry veteran) Bill Doyle and Actavis Executive Chairman Paul Bisaro to the board on April 13, 2015.

Over the course of our ownership, ZTS developed and implemented a number of value-enhancing initiatives including restructuring its supply chain, pursuing organic revenue growth opportunities while reducing costs, and setting a goal of increasing operating margins from ~25% in 2014 to ~34% by 2017. Zoetis outperformed each of these objectives during our ownership.

We sold our remaining shares of Zoetis on November 9th. During our more than two-year ownership, Zoetis generated a total shareholder return of 58%.

From Bill Ackman (Trades, Portfolio)'s Pershing Square third-quarter shareholder letter.

Check out Bill Ackman latest stock trades

Bill Ackman Comments on Zoetis Inc. - Aug 29, 2016

There is still a lot more work to do, but we are pleased with the company's progress over the last several months. Zoetis Inc. (NYSE:ZTS) Zoetis delivered another exceptional quarter of performance. Organic revenue growth was +4%, driven by +13% growth in Zoetis' companion animal segment. Excluding the revenue impact of the company's operational efficiency initiatives, organic revenue growth was 9%. Management's execution of its operational efficiency initiative continues to be excellent. SG&A as a percentage of sales fell by 180bps in the quarter, year-over-year and gross margins expanded 240bps. While we have sold a substantial portion of our investment to raise capital for new investments, we continue to believe that Zoetis' history of strong organic growth and margin expansion will continue.

From Bill Ackman (Trades, Portfolio)'s mid-year 2016 letter.

Check out Bill Ackman latest stock trades

Bill Ackman Comments on Zoetis Inc. - May 11, 2016

Zoetis (NYSE:ZTS) is the only large, independent, publicly traded animal health company in the world. The company has a market capitalization of ~$23 billion and $5 billion in revenue. The Pershing Square funds currently own a 5.0% economic stake in the company, down from 8.6% as a result of a recent block sale.

During the first quarter, adjusted revenue grew 6%. The Companion Animal segment was the star of the quarter, with growth of 20% driven by new product launches. Livestock revenue growth was nominal at 1% due to competition in U.S. swine products and mild U.S. weather.

Gross margins and SG&A spending were both better than expectations. Management continues to execute well on the cost efficiency program announced in May 2015. SG&A fell by 6% YoY, despite six extra days in the quarter. Operating margins expanded ~500 bps from the prior year. Management now believes savings from the efficiency program will exceed the original $300 million targeted when the program was announced last May. All savings from this program are expected to be realized by 2017.

Good performance and favourable FX allowed management to increase earnings guidance by $0.10/share in 2016 and $0.06/share in 2017.

We executed a block sale of 16.85 million shares on May 9th, reducing our ownership of the company from 8.6% to 5.0%. We continue to be pleased with management’s performance and have high expectations for the company. As with CP and Mondelez, we reduced our position for portfolio management reasons.

Bill Doyle, who has represented Pershing Square on the ZTS board since February 4, 2015, will not stand for re-election at the annual meeting on May 12th. We no longer feel that our presence on the board is required as the company continues to generate strong progress as evidenced by first quarter results.

From Bill Ackman (Trades, Portfolio)'s first quarter shareholder letter.

Check out Bill Ackman latest stock trades

Bill Ackman Comments on Zoetis Inc. - Dec 16, 2015

Zoetis, Inc. (NYSE:ZTS)

On November 3rd, Zoetis reported another strong quarter. Operational revenue grew 9% and operational adjusted net income grew 31%, excluding the impact of foreign exchange. Growth was driven by strong performance in the U.S. livestock business, the integration of the Abbott Animal Health business that was acquired in the first quarter of 2015, and growth in recently launched products in the companion animal sector. Reported revenue of $1.2 billion was flat year-on-year, while reported EPS of $0.38 represented a 15% increase over third quarter 2014 reported EPS.

Adjusted diluted net income per share, which excludes purchase accounting adjustments and certain one-time costs, was $0.50. This is an increase of 22% compared to third quarter 2014, and significantly in excess of the Wall Street consensus adjusted EPS estimate of $0.40 per share.

Management continues to demonstrate its expense discipline. Operating expenses grew 3% while operational revenue grew 9% excluding the impact of foreign exchange. Management reaffirmed its commitment to meet or exceed the previously announced $300 million expense reduction target by 2017.

During the quarter, the company announced the $765 million acquisition of PHARMAQ, the global leader in vaccines for aquaculture, or farmed fish. Aquaculture is the fastest growing segment of the global animal health industry and is the only segment in which Zoetis had limited presence. The PHARMAQ acquisition provides a market-leading portfolio of vaccines and pharmaceuticals for farmed fish as well as a late-stage development pipeline anticipated to deliver important new vaccines and next-generation parasiticides in the near term. PHARMAQ is a good strategic fit with Zoetis, and provides another pillar for long-term growth. The company believes this acquisition will enjoy a long period of sustainable growth in revenue, profits, and cash flow when added into its business.

From Bill Ackman (Trades, Portfolio)'s Pershing Square Holdings third quarter 2015 letter to shareholders.

Check out Bill Ackman latest stock trades

Bill Ackman Comments on Zoetis Inc. - Sep 11, 2015

Zoetis, Inc. (NYSE:ZTS)



Second quarter earnings exceeded analyst expectations. Management raised 2015 earnings guidance modestly for the year. Revenue growth in the quarter was impressive. Organic revenue adjusted for foreign exchange was 9%. Approximately 80% of revenue growth in the quarter is attributable to volume growth of recently launched and existing products. Operating expenses, adjusted for foreign exchange, rose only 1%, despite an 11% increase in revenue. Management announced significant progress in its R&D portfolio, including advances in new product innovation and improvements to existing products.



In May, Zoetis announced a large cost restructuring program. Management has begun to take its first steps towards achieving this plan and believes it is on track to deliver its target of at least $300 million of savings, which will increase Zoetis’ operating profit margin from 25% in 2014 to 34% in 2017 according to the company’s second quarter conference call. Thereafter, management expects a combination of continued cost discipline, strong revenue growth, and execution of management’s supply chain efficiency program will result in continuing improvements in operating profit margins.



From Pershing Square's semi-annual 2015 report.



Check out Bill Ackman latest stock trades

Top Ranked Articles about Zoetis Inc

Bill Ackman Expands Chipotle Position, Cuts Zoetis Activist investor trims 3 positions in 4th quarter
Activist investor Bill Ackman (Trades, Portfolio), founder of Pershing Square Capital Management, buys the common stock of companies and pushes for changes so that the market can realize the values of these companies. Like fellow activist investor Carl Icahn (Trades, Portfolio), Ackman buys out-of-favor companies at a discount and sells them when the companies reach their appraised value. Read more...
Bill Ackman Comments on Zoetis Guru stock highlight
On November 9th we sold our last shares of Zoetis (NYSE:ZTS), about two years after we publicly announced an 8.5% ownership stake. Despite the high quality nature of the business and its strong management team, we sold to redeploy the capital in certain new investments. Read more...
Bill Ackman Comments on Zoetis Inc. Guru stock highlight
There is still a lot more work to do, but we are pleased with the company's progress over the last several months. Zoetis Inc. (NYSE:ZTS) Zoetis delivered another exceptional quarter of performance. Organic revenue growth was +4%, driven by +13% growth in Zoetis' companion animal segment. Excluding the revenue impact of the company's operational efficiency initiatives, organic revenue growth was 9%. Management's execution of its operational efficiency initiative continues to be excellent. SG&A as a percentage of sales fell by 180bps in the quarter, year-over-year and gross margins expanded 240bps. While we have sold a substantial portion of our investment to raise capital for new investments, we continue to believe that Zoetis' history of strong organic growth and margin expansion will continue. Read more...
Ackman Sells Nearly a Quarter of Stake in Zoetis Guru trims position by more than 6 million shares
Bill Ackman (Trades, Portfolio) of Pershing Square Capital Management LP reduced his stake in Zoetis Inc. (NYSE:ZTS) for the second time this year with the sale of 6,081,841 shares for $47.69 per share on July 7. Read more...
Bill Ackman Slashes Position in Zoetis Company's financial results have been struggling over the past 12 months
Guru Bill Ackman (Trades, Portfolio) and founder of Pershing Square Capital Management LP slashed his position in Zoetis Inc. (NYSE:ZTS) on May 9. Read more...
Bill Ackman Comments on Zoetis Inc. Guru stock highlight
Zoetis (NYSE:ZTS) is the only large, independent, publicly traded animal health company in the world. The company has a market capitalization of ~$23 billion and $5 billion in revenue. The Pershing Square funds currently own a 5.0% economic stake in the company, down from 8.6% as a result of a recent block sale. Read more...
Bill Ackman Is Selling Zoetis but Other Gurus Are Jumping In Ackman cuts his second largest holding
Bill Ackman (Trades, Portfolio) is said to be preparing to partially withdraw from pet health care company Zoetis (NYSE:ZTS) where he had waged an activist campaign, but first-quarter portfolios rolling in this month already show several other well-known managers have piled in. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 32.41
ZTS's P/E(ttm) is ranked lower than
63% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.40 vs. ZTS: 32.41 )
Ranked among companies with meaningful P/E(ttm) only.
ZTS' s P/E(ttm) Range Over the Past 10 Years
Min: 27.31  Med: 37.25 Max: 69.75
Current: 32.41
27.31
69.75
PE(NRI) 32.41
ZTS's PE(NRI) is ranked lower than
63% of the 543 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.84 vs. ZTS: 32.41 )
Ranked among companies with meaningful PE(NRI) only.
ZTS' s PE(NRI) Range Over the Past 10 Years
Min: 27.31  Med: 37.25 Max: 69.75
Current: 32.41
27.31
69.75
Price/Owner Earnings (ttm) 61.83
ZTS's Price/Owner Earnings (ttm) is ranked lower than
76% of the 300 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.72 vs. ZTS: 61.83 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ZTS' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 53.01  Med: 117.86 Max: 341.77
Current: 61.83
53.01
341.77
P/B 17.72
ZTS's P/B is ranked lower than
96% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.02 vs. ZTS: 17.72 )
Ranked among companies with meaningful P/B only.
ZTS' s P/B Range Over the Past 10 Years
Min: 12.62  Med: 17.93 Max: 24.4
Current: 17.72
12.62
24.4
P/S 5.45
ZTS's P/S is ranked lower than
68% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.06 vs. ZTS: 5.45 )
Ranked among companies with meaningful P/S only.
ZTS' s P/S Range Over the Past 10 Years
Min: 3.11  Med: 4.51 Max: 5.7
Current: 5.45
3.11
5.7
PFCF 53.58
ZTS's PFCF is ranked lower than
75% of the 226 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.72 vs. ZTS: 53.58 )
Ranked among companies with meaningful PFCF only.
ZTS' s PFCF Range Over the Past 10 Years
Min: 25.69  Med: 48.89 Max: 90.29
Current: 53.58
25.69
90.29
POCF 37.36
ZTS's POCF is ranked lower than
77% of the 295 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.98 vs. ZTS: 37.36 )
Ranked among companies with meaningful POCF only.
ZTS' s POCF Range Over the Past 10 Years
Min: 21.62  Med: 33.68 Max: 41.91
Current: 37.36
21.62
41.91
EV-to-EBIT 21.56
ZTS's EV-to-EBIT is ranked lower than
52% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.65 vs. ZTS: 21.56 )
Ranked among companies with meaningful EV-to-EBIT only.
ZTS' s EV-to-EBIT Range Over the Past 10 Years
Min: 20.2  Med: 25.7 Max: 41.7
Current: 21.56
20.2
41.7
EV-to-EBITDA 18.40
ZTS's EV-to-EBITDA is ranked lower than
54% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.72 vs. ZTS: 18.40 )
Ranked among companies with meaningful EV-to-EBITDA only.
ZTS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 16.7  Med: 20.6 Max: 32.1
Current: 18.4
16.7
32.1
PEG 2.47
ZTS's PEG is ranked lower than
61% of the 282 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. ZTS: 2.47 )
Ranked among companies with meaningful PEG only.
ZTS' s PEG Range Over the Past 10 Years
Min: 2.47  Med: 3.17 Max: 3.46
Current: 2.47
2.47
3.46
Current Ratio 3.03
ZTS's Current Ratio is ranked higher than
59% of the 726 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. ZTS: 3.03 )
Ranked among companies with meaningful Current Ratio only.
ZTS' s Current Ratio Range Over the Past 10 Years
Min: 2.15  Med: 2.65 Max: 3.19
Current: 3.03
2.15
3.19
Quick Ratio 1.69
ZTS's Quick Ratio is ranked lower than
54% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. ZTS: 1.69 )
Ranked among companies with meaningful Quick Ratio only.
ZTS' s Quick Ratio Range Over the Past 10 Years
Min: 1.33  Med: 1.47 Max: 2
Current: 1.69
1.33
2
Days Inventory 329.42
ZTS's Days Inventory is ranked lower than
94% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.19 vs. ZTS: 329.42 )
Ranked among companies with meaningful Days Inventory only.
ZTS' s Days Inventory Range Over the Past 10 Years
Min: 117.43  Med: 284.81 Max: 329.42
Current: 329.42
117.43
329.42
Days Sales Outstanding 68.18
ZTS's Days Sales Outstanding is ranked higher than
55% of the 628 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.32 vs. ZTS: 68.18 )
Ranked among companies with meaningful Days Sales Outstanding only.
ZTS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 68.18  Med: 74.93 Max: 91.07
Current: 68.18
68.18
91.07
Days Payable 58.06
ZTS's Days Payable is ranked lower than
60% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.12 vs. ZTS: 58.06 )
Ranked among companies with meaningful Days Payable only.
ZTS' s Days Payable Range Over the Past 10 Years
Min: 47.28  Med: 61.59 Max: 110.66
Current: 58.06
47.28
110.66

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.73
ZTS's Dividend Yield is ranked lower than
80% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.61 vs. ZTS: 0.73 )
Ranked among companies with meaningful Dividend Yield only.
ZTS' s Dividend Yield Range Over the Past 10 Years
Min: 0.21  Med: 0.71 Max: 1.08
Current: 0.73
0.21
1.08
Dividend Payout 0.23
ZTS's Dividend Payout is ranked higher than
86% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.36 vs. ZTS: 0.23 )
Ranked among companies with meaningful Dividend Payout only.
ZTS' s Dividend Payout Range Over the Past 10 Years
Min: 0.19  Med: 0.24 Max: 0.49
Current: 0.23
0.19
0.49
Dividend Growth (3y) 24.90
ZTS's Dividend Growth (3y) is ranked higher than
76% of the 285 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.10 vs. ZTS: 24.90 )
Ranked among companies with meaningful Dividend Growth (3y) only.
ZTS' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 24.9
Current: 24.9
0
24.9
Forward Dividend Yield 0.80
ZTS's Forward Dividend Yield is ranked lower than
78% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.35 vs. ZTS: 0.80 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.73
ZTS's Yield on cost (5-Year) is ranked lower than
81% of the 764 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.14 vs. ZTS: 0.73 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ZTS' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.21  Med: 0.71 Max: 1.08
Current: 0.73
0.21
1.08
3-Year Average Share Buyback Ratio 0.50
ZTS's 3-Year Average Share Buyback Ratio is ranked higher than
82% of the 436 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. ZTS: 0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ZTS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.1  Med: 0 Max: 0
Current: 0.5
-0.1
0

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 4.59
ZTS's Price/Projected FCF is ranked lower than
99.99% of the 320 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. ZTS: 4.59 )
Ranked among companies with meaningful Price/Projected FCF only.
ZTS' s Price/Projected FCF Range Over the Past 10 Years
Min: 4.5  Med: 4.59 Max: 4.6
Current: 4.59
4.5
4.6
Price/Median PS Value 1.21
ZTS's Price/Median PS Value is ranked lower than
99.99% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. ZTS: 1.21 )
Ranked among companies with meaningful Price/Median PS Value only.
ZTS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.79  Med: 1.06 Max: 1.21
Current: 1.21
0.79
1.21
Price/Peter Lynch Fair Value 3.15
ZTS's Price/Peter Lynch Fair Value is ranked lower than
99.99% of the 168 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.53 vs. ZTS: 3.15 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ZTS' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 3.1  Med: 3.16 Max: 3.16
Current: 3.15
3.1
3.16
Earnings Yield (Greenblatt) (%) 4.62
ZTS's Earnings Yield (Greenblatt) (%) is ranked higher than
64% of the 835 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. ZTS: 4.62 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ZTS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.4  Med: 3.9 Max: 4.9
Current: 4.62
2.4
4.9
Forward Rate of Return (Yacktman) (%) 11.91
ZTS's Forward Rate of Return (Yacktman) (%) is ranked higher than
55% of the 358 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.67 vs. ZTS: 11.91 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ZTS' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 11.8  Med: 12.5 Max: 16
Current: 11.91
11.8
16

More Statistics

Revenue (TTM) (Mil) $4,888
EPS (TTM) $ 1.65
Beta1.25
Short Percentage of Float1.82%
52-Week Range $39.35 - 56.50
Shares Outstanding (Mil)491.96

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 5,137 5,439 5,706
EPS ($) 2.33 2.66 2.97
EPS w/o NRI ($) 2.33 2.66 2.97
EPS Growth Rate
(3Y to 5Y Estimate)
20.23%
Dividends Per Share ($) 0.41 0.48
» More Articles for ZTS

Headlines

Articles On GuruFocus.com
Bill Ackman Expands Chipotle Position, Cuts Zoetis Feb 15 2017 
Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary Feb 14 2017 
Manning & Napier’s Top 3 New Holdings Jan 26 2017 
Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary Jan 24 2017 
5 Companies Hit 52-Week Highs Jan 05 2017 
Bill Ackman Comments on Zoetis Dec 09 2016 
Bill Ackman Discusses Rebounding Stocks in Pershing Square 3rd-Quarter Letter Dec 08 2016 
'Kittens Equal Happiness': GAMCO Analyst on Zoetis, Heska, Smuckers Oct 07 2016 
Bill Ackman Comments on Zoetis Inc. Aug 29 2016 
Bill Ackman Raises $1.4 Billion in Canadian Pacific Railway Sell Aug 04 2016 

More From Other Websites
Zoetis to Participate in the Cowen and Company 37th Annual Health Care Conference Feb 17 2017
Zoetis (ZTS) Beats Q4 Earnings Estimates, Lowers Outlook Feb 16 2017
Edited Transcript of ZTS earnings conference call or presentation 16-Feb-17 1:30pm GMT Feb 16 2017
Billionaire Bill Ackman’s Pershing Square Boosts Bet on Fast Food Industry, Cuts Down on... Feb 16 2017
Zoetis Reports Earnings Beat, So Why Are Shares Plummeting? Feb 16 2017
Zoetis (ZTS) Tops on Earnings in Q4, Updates View Feb 16 2017
Zoetis tops 4Q profit forecasts Feb 16 2017
Zoetis tops 4Q profit forecasts Feb 16 2017
Q4 2016 Zoetis Inc Earnings Release - Before Market Open Feb 16 2017
ZOETIS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 16 2017
Zoetis Reports Fourth Quarter and Full Year 2016 Results Feb 16 2017
Bill Ackman Expands Chipotle Position, Cuts Zoetis Feb 15 2017
Zoetis Receives European Commission Approval for Stronghold® Plus Feb 15 2017
Zoetis Receives European Commission Approval for Stronghold® Plus Feb 15 2017
Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More Feb 15 2017
ZOETIS INC. Files SEC form 8-K, Regulation FD Disclosure Feb 14 2017
Zoetis Declares Second Quarter 2017 Dividend Feb 14 2017
Use Pullback on Zoetis to Do Some Buying Feb 13 2017
Will Zoetis (ZTS) Disappoint Estimates This Earnings Season? Feb 10 2017
BMO Asset Management to Launch New ETFs on NEO Feb 07 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)